

4DMedical expands contract with Stanford to include CT:VQ™

17 June 2025

Highlights

- CT:VQ™ contracted for research and evaluation at Stanford University ahead of FDA clearance
 - Part of Stanford Medicine, the 3D and Quantitative Imaging Laboratory (3DQ Lab) renews contract and upgrades its subscription for 4DMedical imaging solutions
 - Alongside CT:VQ™, additional 4DMedical products licensed include CT LVAS™ and IQ-UIP™, which are both already cleared for clinical use in the U.S.
-

Melbourne, Australia, 17 June 2025: 4DMedical Limited (ASX: 4DX, “4DMedical”, or the “Company”), a global leader in respiratory imaging technology, today announces a renewed and significantly expanded contract with Stanford University’s 3DQ Lab, one of the most respected and influential medical imaging innovation centres in the United States.

Stanford upgrades contract with 4DMedical

Part of Stanford Medicine, the 3D Quantitative Imaging Laboratory (3DQ Lab) is globally recognised for its role in evaluating, validating and operationalising next-generation imaging technologies across clinical research and patient care. As a key opinion leading (KOL) site, its adoption of emerging technologies not only shapes medical practice within Stanford’s health system, but also influences broader U.S. healthcare standards and innovation pathways.

Under the renewed one-year subscription agreement, Stanford has licensed a comprehensive suite of advanced image analysis products from 4DMedical. The annual subscription allows for up to 20,000 CT scan analysis jobs per subscription year. In addition to renewing the license for all products under the existing contract, Stanford has upgraded its package to now include:

- CT Lung Ventilation Analysis Software (CT LVAS™), 4DMedical’s fully automated tool providing functional assessment of lung ventilation directly from routine CT scans;
- IQ-UIP™, 4DMedical’s AI-based solution that detects usual interstitial pneumonia (UIP) patterns to aid in diagnosing fibrotic interstitial lung diseases; and
- CT:VQ™ (for internal research use), 4DMedical’s contrast-free ventilation perfusion product.

Significantly, Stanford has requested to include CT:VQ™ in the contract for research and evaluation ahead of expected FDA-clearance. CT:VQ™ is a transformative imaging solution from 4DMedical that delivers comprehensive ventilation and perfusion insights without the need for radioactive tracers or contrast agents, offering a safer, faster, and more scalable alternative to traditional nuclear medicine VQ scans.

As 4DMedical continues to expand its U.S. footprint, partnerships with leading academic medical centres (AMCs) like Stanford play a pivotal role in supporting clinical validation, market readiness, and broader adoption of 4DMedical’s unique functional and structural lung imaging solutions. This expanded contract is another validation of 4DMedical’s strategic focus on delivering next-generation pulmonary imaging capabilities to meet urgent healthcare needs.



4DMedical MD/CEO and Founder Andreas Fouras said:

Stanford's 3DQ Lab is one of the most influential medical imaging research centres in the world, and the renewal and expansion of their contract shows the value they see in 4DMedical's technology. In addition, their decision to also include our CT:VQ™ technology in the contract, ahead of FDA clearance, is an extraordinary validation of the strength of the interest in this revolutionary product. CT:VQ's inclusion at Stanford will accelerate both clinical insight and market momentum, as we move closer to FDA clearance and large-scale U.S. deployment.

—ENDS—

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical's innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical's solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of **Imbio**, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio's AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical's mission to redefine respiratory healthcare.

To learn more, please visit www.4dmedical.com